Nicola Fenwick BMedSc

Institute of Cancer and Genomic Sciences
Trial Manager

Contact details

+44 (0)121 415 8782
+44 (0)121 414 3700
Cancer Research UK Clinical Trials Unit
Sir Robert Aitken Institute for Clinical Research
Institute of Cancer and Genomic Sciences
University of Birmingham
Vincent Drive
Birmingham, B15 2TT

Nicola Fenwick is Team Manager for the Therapy Acceleration Programme (Haematology) at the Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences.


  • BMedSc (Hons) Medical Science 2000


Nicola Fenwick graduated with a BMedSc (Hons) from the University of Birmingham in 2000. She then went to work as a graduate technician at the Binding Site Ltd, where she was responsible for the development of diagnostic kits. She then returned to the University of Birmingham in 2004 as a Trial Monitor for the Cancer Research UK Clinical Trials Unit (CRCTU).

In 2005 Nicola was appointed as a Trial Coordinator within CRCTU and was made responsible for the management of two large, multi-centre, clinical trials looking at the effects of chemotherapy regimens in breast cancer.

She was then appointed as a Senior Trial Coordinator in 2008, leading Leukeamia and Lymphoma Research’s Early Phase Trials Team (LLR ETT). Since its inception the LLR ETT has supported over 15 UK Investigators apply for clinical grant funding for early phase clinical trials.

At the beginning of 2011 Nicola was appointed Team leader and helped secure an award to expand the LLR ETT and establish the LLR Therapy Acceleration Programme Team within CRCTU.

In May 2014 she was appointed Team Leader for the Children’s Cancer Trials Team at CRCTU. Helping to deliver the national portfolio of trials for children with cancer. 


Research Themes

Clinical Trials. Children’s, Paediatric, Cancer, Haematology, Lymphoma, Breast Cancer.

Other activities

  • National Cancer Research Institute Haemato-Oncology Clinical Studies Group Project Officer 2008 - 2014


Khan J, Yap C, Clark R, Fenwick N, Marin D (2013): Practical implementation of an adaptive phase I/II design in chronic myeloid leukaemia: evaluating both efficacy and toxicity using the EffTox design. Trials 2013, 14(Suppl 1):P20 

Earl, H.M. Vallier, A.L. Hiller, L. Fenwick, N. Young, J. Iddawela, M. Abraham, J. Hughes-Davies, L. Gounaris, I. McAdam, K. Houston, S. Hickish, T. Skene, S. Chan, S. Dean, S. Ritchie, D. Laing, R. Harries, M. Gallagher, C. Wishard, G. Dunn, J. Provenzano, E. Caldas, C. for the Neo-tAnGo Investigators.  (2013), Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and aplictaxel for wmen with high-risk early breast cancer (Neo0tAnGo): an open-label, 2x2 factorial randomised phase 3 trial. Lancet Oncol 2013. Published online December 19, 2013. and online comment

Provenzano, E. A-L Vallier, A.L. Champ, R. Walland, K. Bowden, S. Grier, A, Fenwick, N. Abraham, J. Iddawela, M. Caldas, C. Hiller, L. Dunn, J. Earl, H.M. (2013), A central review of histology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial. British Journal of Cancer (2013) 108, 866–872. doi:10.1038/bjc.2012.547

H. M. Earl, A. Vallier, L. Hiller, N. Fenwick, M. Iddawela, L. Hughes-Davies, E. Provenzano, K. McAdam, T. Hickish, C. Caldas, for NeotAnGo Investigators (2009), Neo-tAnGo: A neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel ± gemcitabine in the treatment of women with high-risk early breast cancer (EBC): First report of the primary endpoint, pathological complete response (pCR), J Clin Oncol 27:15s, 2009 (suppl; abstr 522)